SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Hinterlegungsschein · US82686Q1013 · SLN · A2QB4J (XNAS)
Übersicht
5,17 USD
-2,08 % -0,11 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
10.06.2025 19:59

Aktuelle Kurse von SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
SLN
USD
10.06.2025 19:59
5,17 USD
5,28 USD
-2,08 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-2,08 % -8,98 % 39,73 % 7,71 % -35,29 % -74,76 % -73,49 %

Firmenprofil zu SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE Hinterlegungsschein

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Unternehmensdaten

Name SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Firma Silence Therapeutics plc
Symbol SLN
Website https://www.silence-therapeutics.com
Heimatbörse XNAS NASDAQ
WKN A2QB4J
ISIN US82686Q1013
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Mr. Craig A. Tooman M.B.A.
Marktkapitalisierung 149 Mio
Land Großbritannien und Nordirland
Währung USD
Mitarbeiter 0,1 T
Adresse 72 Hammersmith Road, W14 8TH London
IPO Datum 2020-09-08

Ticker Symbole

Name Symbol
Frankfurt XRP2.F
NASDAQ SLN

Weitere Aktien

Investoren die SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE die halten, haben auch folgende Aktien im Depot:
GOOSEHEAD INSURANCE INC - CLASS A
GOOSEHEAD INSURANCE INC - CLASS A Aktie
PIMCO CALIFA MUNICIPAL INCME FUND III  OF BENEFICIAL INTEREST
PIMCO CALIFA MUNICIPAL INCME FUND III OF BENEFICIAL INTEREST Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025